All Whitepapers

Discover MapLab, an all-in-one offering for healthcare and Life Sciences companies to generate insights into disease trends, treatment pathways, patient populations, and a host of other complex research questions.

Insight into the complete patient journey not only offers new ways to empower field teams, it is also key to surfacing more HCPs who treat patients with your target condition.

The rapid evolvement of precision oncology requires real-world data generated at a scale that unlocks insights that can not be provided from clinical trial evidence. Machine learning and large language models can be used to quickly identify information, supporting custom integrated real-world evidence solutions to make informed decisions.

MilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.

Biopharma companies and contract research organizations (CROs) adopted decentralized or digital clinical trials (DCTs) to reduce contact, improve the patient experience and keep studies on track during the pandemic. It’s already clear that the virtual approach of DCTs are benefiting life science organizations. From improvements in clinical trial operations such as enhanced patient engagement and site experience to cost savings and better data integration, the clinical trial dynamic has shifted and supports DCTs as a legitimate way to execute studies.

AdTech (Advertising Technology) and AI/ML (Artificial Intelligence/Machine Learning) are playing significant roles in transforming the healthcare industry, particularly in areas like digital marketing and clinical trials. Let's explore each area in more detail.

Limited field rep coverage is something all pharma brands struggle with at one time or another. Minimizing the negative impact with solutions that keep your brand top-of-mind. Here’s one solution that not only fueled a successful launch but beat recent quarterly earnings by 14%

What the Changing Healthcare Landscape Demands of Future MA Professionals?

Increasingly clinical pharma and biotech organizations are deciding to commercialize on their own; just as Contract Research Organizations (CROs) transformed clinical trial operations, Contract Commercial Services are transforming commercial operations. Emerging service models offer new options for clinical organizations. In this podcast, Brent Herspiegel, CEO, and Santosh Naik, Partner, Herspiegel Consulting, share the considerations for pharma and biotech organizations when deciding on their commercial path and partner. How Contract Commercial Services can mitigate common launch risks, what we can learn from Herspiegel Consulting’s experience with 100+ pharma product launches.

While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.

Compelling messaging is at the core of every effective pharmaceutical marketing strategy. Whether it is the launch of a new drug or a message refresh project, crisp copy that builds an emotional connection with your target market can help keep communication impactful, without making it highly complex or over-simplistic. Many pharmaceutical companies produce large amounts of unremarkable copy which doesn’t convert. To help you cut through the noise of communication of rival pharma companies, Newristics has created the Ultimate Pharma Messaging Guide with 20 guiding principles that have been scientifically proven to turbocharge pharma communications.

In this application note you will learn the importance of reproducible gene expression quantitation to evaluate host immune response for optimizing safety of gene therapies.

When a company reaches late-stages of clinical trials testing new drugs, systems need to be created to manage the manufacturing, sales, costs, internal controls, and more. A successful transition into commercializing a new drug depends on putting in place the right infrastructure and systems.

Readily available real-world data and advanced solutions are being used to stitch together the full patient journey, and these longitudinal insights are being used to identify and characterize trial populations and inform clinical trial design and execution strategies.

IT Leaders in Life Sciences discuss the consolidation of the learning tech environment to help shift the training effectiveness conversation from anecdotal evidence to data-driven understanding.

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. While these third-party relationships can be full of risk and regulatory challenges, the right tech can help you navigate the complexities of compliance.

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, new systems were quickly — and possibly haphazardly — put in place to handle snowballing transparency reporting requirements. Now the cracks are beginning to show, and PLS companies are realizing the true cost of transparency reporting.

Digital health platforms, modern delivery models, and edge technologies can transform the way life sciences companies create a virtuous circle of value generation, equipping patients with capabilities that improve health outcomes while providing businesses with valuable data and insights to drive new research, improve stakeholders’ experiences, and accelerate growth. Solutions designed to serve clinical trial participants outside of a clinical setting should be considered as companion services for commercial therapies to drive greater adherence as well as real-world evidence.

Learn about the evolving cyber-threat landscape affecting the pharmaceutical industry and the recommended approach to addressing those threats.

There are three phases of digital transformation needed to reimagine business models, achieve better performance, and create long-term sustainable advantage. It starts with changing our labs—the technologies, processes, ways of working, and data solutions.

According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.

In this paper, learn about a variety of genetic analysis methods and how they’re valuable in ensuring that ex vivo human cells used for cell‑based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Download the white paper and read more about the importance of quality control (QC) for isolated human cells and tissues.

For biopharmaceutical developers, optimizing R&D investment in new technologies is an essential way to gain and sustain a competitive edge. Clinical trials present a tremendous opportunity to leverage advanced genetics technologies and practices to improve efficiency and reduce costs.